Man Group PLC Abb Vie Inc. Call Options Transaction History

Man Group PLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $5.95 Million - $7.24 Million	36,300 Added 80.67%	81,300 $16.1 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $1.46 Million - $1.7 Million	9,400 Added 26.4%	45,000 $7.72 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $575,352 - $655,560	-3,600 Reduced 9.18%	35,600 $6.48 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $5.39 Million - $6.07 Million	39,200 New	39,200 $6.07 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $132,510 - $164,900	1,000 Added 1000.0%	1,100 $148,000
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $14,461 - $16,654	100 New	100 $15,000

3,848

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $313B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.